Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue Plasminogen Activator

Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue... REVIEW ARTICLE Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue Plasminogen Activator A Case Report and Review of Treatment Options Gregory S. Ahearn, MD; Denis Hadjiliadis, MD; Joseph A. Govert, MD; Victor F. Tapson, MD hromboembolic disease is an important cause of morbidity and mortality during preg- 1 2 nancy. Berg and colleagues found that 11% of maternal deaths during pregnancy were related to pulmonary embolism (PE). Another study revealed that up to 40% of preg- T nant women with asymptomatic deep vein thrombosis (DVT) may also have concur- rent PE. Women are at increased risk for DVT and PE during pregnancy for several reasons. Preg- nancy is a thrombophilic state; fibrinogen levels are increased, and during the final trimester there is a decrease in fibrinolytic activity. In addition, the gravid uterus causes compression and stasis in the lower extremities and pelvic veins favoring thrombosis. Finally, women with a history of throm- botic complications during pregnancy have an increased prevalence of genetic mutations related to coagulation. Traditionally, thromboembolic disease split products, which are present after during pregnancy has been treated with thrombolytic therapy. The decision to em- unfractionated and, more recently, low- bark on high-risk therapy for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue Plasminogen Activator

Download PDF
7 pages

Loading next page...
 
/lp/american-medical-association/massive-pulmonary-embolism-during-pregnancy-successfully-treated-with-gZlWrunHIA

References (94)

Publisher
American Medical Association
Copyright
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.162.11.1221
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue Plasminogen Activator A Case Report and Review of Treatment Options Gregory S. Ahearn, MD; Denis Hadjiliadis, MD; Joseph A. Govert, MD; Victor F. Tapson, MD hromboembolic disease is an important cause of morbidity and mortality during preg- 1 2 nancy. Berg and colleagues found that 11% of maternal deaths during pregnancy were related to pulmonary embolism (PE). Another study revealed that up to 40% of preg- T nant women with asymptomatic deep vein thrombosis (DVT) may also have concur- rent PE. Women are at increased risk for DVT and PE during pregnancy for several reasons. Preg- nancy is a thrombophilic state; fibrinogen levels are increased, and during the final trimester there is a decrease in fibrinolytic activity. In addition, the gravid uterus causes compression and stasis in the lower extremities and pelvic veins favoring thrombosis. Finally, women with a history of throm- botic complications during pregnancy have an increased prevalence of genetic mutations related to coagulation. Traditionally, thromboembolic disease split products, which are present after during pregnancy has been treated with thrombolytic therapy. The decision to em- unfractionated and, more recently, low- bark on high-risk therapy for

Journal

JAMA Internal Medicine – American Medical Association

Published: Jun 10, 2002

There are no references for this article.